Axitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptors, has demonstrated modest efficacy when applied as a single agent in the setting of advancedstage melanoma. On the basis of the reported ability of axitinib to 'normalize' the tumor vasculature, we hypothesize that combination therapy using axitinib plus specific peptide-based vaccination would promote superior activation and recruitment of protective T cells into the melanoma microenvironment, leading to enhanced treatment benefit. Using a subcutaneous M05 (B16.OVA) melanoma model, we observed that a treatment regimen consisting of a 7-day course of axitinib (0.5 mg/day provided orally) combined with a subcutaneous vaccine [ovalbumin (OVA) peptide-pulsed syngenic dendritic cells adenovirally engineered to produce IL-12p70] yielded superior protection against melanoma growth and extended overall survival when compared with animals receiving either single modality therapy. Treatment benefits were associated with: (a) a reduction in suppressor cell (myeloid-derived suppressor cells and Treg) populations in the tumor, (b) activation of tumor vascular endothelial cells, and (c) activation and recruitment of type-1, vaccineinduced CD8 + T cells into tumors. These results support the therapeutic superiority of combined vaccine + axitinib immunotherapy and the translation of such approaches into the clinic for the treatment of patients with advancedstage melanoma.
Introduction
Tumor size is physiologically constrained by a supportive vascular system that can provide a sufficient level of nutrients, while coordinately discharging waste materials [1] . Vascular endothelial growth factor receptors (VEGFRs) are critically involved in neoangiogenic pathways that support new blood vessel formation in the tumor microenvironment (TME). The production of VEGF in the TME serves to recruit, expand, and differentiate (vascular) endothelial cell progenitors [2] . Clinical efforts to block the VEGF-signaling cascade using bevacizumab (an antagonist anti-VEGF monoclonal antibody) in combination with standard therapies has demonstrated promising results in patients with metastatic melanoma, suggesting the utility of antiangiogenic treatment strategies against advanced-stage disease [3] [4] [5] [6] .
An improved understanding of the molecular targets governing tumor angiogenesis has led to the development of a large number of small-molecule drugs that are capable of blocking signaling pathways involved in propagating and maintaining a tumor-supportive stroma [7] . Axitinib is a potent second-generation tyrosine kinase inhibitor that blocks signaling through VEGFR-1, VEGFR-2, and VEGFR-3 (as well as the platelet-derived growth factor receptor and c-kit/CD117) that has been clinically applied as a monotherapy in the setting of a broad range of cancer types [8] . Food and Drug Adminisitration approval is currently being sought for the use of axitinib in patients with metastatic renal cell carcinoma, following the completion of a phase III clinical trial (AXIS trial) showing an enhancement in progressionfree survival in axitinib-treated patients who were refractory to first-line therapies [9] .
Preclinical studies have also indicated that axitinib mediates antiangiogenic and antitumor effects in the melanoma-bearing host [10] . In human xenograft models, axitinib monotherapy inhibited primary melanoma development and controlled distant metastasis. Axitinib also enhanced the protection associated with bevacizumab therapy when used in a combination protocol against orthotopic M24met xenografts [10] .
Recently, the results of a multicenter phase II study of single-agent axitinib therapy in patients with metastatic melanoma were published [11] . Axitinib was found to be generally well tolerated, with treatment leading to reductions in the plasma levels of soluble VEGFR-2 and VEGFR-3 and increased levels of soluble VEGF ligand. Treatment with axitinib was associated with an 18.8% objective response rate (ORR), a frequency that compares favorably with standard melanoma therapies, including chemotherapy and rhIL-2 [12] .
Overall, these results justify the expanded use of axitinib in the setting of melanoma, particularly when combined with nonredundant therapies (such as immunotherapies). Specific vaccination represents one valid coapplied approach as melanoma and/or melanoma-associated stromal cells can be effectively targeted and destroyed by specific immune effector cells [13] [14] [15] . As vaccination also results in the expansion of memory T-cell populations, such approaches have a theoretical advantage in providing sustained surveillance by a protective immune repertoire. In the current report, we observed that combined therapy of mice bearing established M05 (B16.OVA) melanoma with specific ovalbumin (OVA) peptide-based vaccination + axitinib was superior in efficacy when compared with either single component modality. Axitinib appeared to serve as an effective adjuvant to vaccination by removing endogenous regulatory cell populations and by activating the tumor vasculature, allowing for the facilitated recruitment of vaccine-induced type-1 CD8 + T cells. These results support the translational use of combined vaccine (targeting tumor cells and/or tumor-associated stromal cells [14, 15] ) + axitinib-based therapies for the treatment of patients with advanced-stage melanoma.
Materials and methods

Mice
Female 6-8-week-old C57BL/6 and OT-1 mice were purchased from the Jackson laboratory (Bar Harbor, Maine, USA). Animals were maintained in microisolator cages and handled under aseptic conditions following an Institutional Animal Care and Use Committee-approved protocol.
Cell lines and culture
The MO5 (B16.OVA) melanoma cell line was utilized for tumor challenge studies. Cells were free of Mycoplasma contamination and maintained in complete media (CM) [RPMI 1640 media supplemented with 10% heatinactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10 mmol/l L-glutamine (all from Life Technologies, Grand Island, New York, USA)] at 371C with 5% CO 2 . The expression of transgene OVA in M05 cells was maintained under culture selection with G418 (Life Technologies).
Peptides
OVA peptides OVA 257-264 (SIINFEKL; presented by H-2K b to CD8 + T cells [16] ) and OVA 323-339 (ISQAVHAA-HAEINEAGR; presented by H-2IA b to CD4 + T cells [16] ) were synthesized to more than 96% purity by 9-fluorenylmethoxycarbonyl (Fmoc) chemistry by the University of Pittsburgh Cancer Institute's Peptide Synthesis Facility (a Shared Resource).
Vaccine generation
Dendritic cells (DCs) were generated from the bone marrow of tibias/femurs from naive mice as described previously [17, 18] . Briefly, bone-marrow-derived cells were cultured in CM over a period of 5 days with 1000 U/ml of rmGM-CSF and rmIL-4 (both from Peprotech, Rocky Hill, New Jersey, USA). CD11c + cells were subsequently purified using MACS bead positive selection (Miltenyi Biotec, Cambridge, Massachusetts, USA) and infected at a multiplicity of infection equal to 50 with an adenoviral vector encoding murine IL-12p70 (Ad.mIL-12p70). The adenoviral vector was produced and provided by the University of Pittsburgh Cancer Institute's Vector Core Facility (a Shared Resource). Transduced DCs were maintained in CM an additional 48 h in the presence of rmGM-CSF and rmIL-4. On day 7, the IL-12 gene-modified DCs (DC.IL12) were loaded with a equimolar mixture (each at 10 mmol/l) of the OVA 257-264 and OVA 323-339 peptides for 4 h at 371C before washing with PBS and injecting the antigenloaded DC.IL12 subcutaneously into mice as a vaccine.
Tumor therapy model
Mice were challenged subcutaneously (right flank) with 2 Â 10 5 MO5 melanoma cells, and tumors were allowed to progress 7 days before randomization into groups of five animals each with comparable mean tumor sizes/group. Animals were then left untreated or they were vaccinated (subcutaneously, left flank) with 1 Â 10 6 OVA peptidepulsed DC.IL12 cells on days 7 and 14 after the MO5 challenge. Axitinib (0.5 mg/day; Santa Cruz Biotechnology, Santa Cruz, California, USA) was dissolved in 50 ml Labrasol (Gattefossé Canada, Toronto, Canada) and delivered through an oral gavage daily to select groups of mice for 1 week beginning on day 7. Tumor growth was monitored every 3-4 days and measured using Vernier calipers. MO5 tumor size was recorded in mm 2 (mean±SD) on the basis of the product of orthogonal measurements.
Determination of OVA-specific T-cell response
At time points ranging from 7 to 35 days after MO5 tumor inoculation, tumor-infiltrating lymphocytes (TILs) and tumor-draining lymph nodes (TDLNs) were harvested from euthanized mice. Single-cell suspensions were generated from tumors by enzymatic digestion using DNase I, collagenase, and hyaluronidase (all from Sigma-Aldrich, St Louis, Missouri, USA), and from TDLNs by mechanical disruption, with T cells subsequently isolated using CD3-MACS beads (Miltenyi Biotec). T cells were pooled between three animals per group and stimulated 5 days in vitro with irradiated (100 Gy) MO5 tumor cells at an effector-to-target (E:T) ratio of 10 : 1. T cells were then transferred to 96-well round bottom plates (Corning, Corning, New York, USA) and incubated with syngenic DCs prepulsed with the OVA 257-264 (SIINFEKL) or no peptide at a 10 : 1 E:T cell ratio for 48 h. Cell-free supernatants were harvested and assessed for mIFN-g content using a specific ELISA kit (BD Biosciences, San Jose, California, USA; with a lower detection limit of 31.3 pg/ml). Data are reported as mean interferon g (IFN-g) levels (pg/ml) of triplicate determinations ±SD.
Flow cytometry
Single-cell suspensions and CD3 + TILs were stained with the following directly conjugated antimouse antibodies (all from BD Biosciences): fluorescein isothiocyanate (FITC)anti-CD8, FITC-anti-CD4, FITC-anti-CD11b, PE-anti-Gr1, and PE-anti-Foxp3. For Foxp3-specific staining, cells were first labeled with the FITC-anti-CD4 antibody before incubation with the PE-anti-Foxp3 antibody using a permeabilization/fixation buffer kit as recommended by the manufacturer (eBioscience, San Diego, California, USA). In additional experiments, a PE-conjugated H-2K b / SIINFEKL tetramer (Beckman Coulter, Brea, California, USA) was utilized to assess OVA-specific CD8 + T-cell frequency. Tetramer staining was carried out in accordance with the manufacturer's suggested protocol. Flow cytometry was performed using Cell Quest software and a FACscan flow cytometer (Becton Dickinson, San Jose, California, USA), with FlowJo software (Tree Star, Ashland, Oklahoma, USA) used for data analysis. Data are reported as absolute cell number±SD, which was determined by multiplying the percentage of viable flowgated cells by the total viable cell yield obtained from each tissue.
Reverse transcription polymerase chain reaction
Total RNA was extracted from tumor tissues at 7, 10, 14, 20, 28, and 35 days after MO5 inoculation using TRIzol reagent (Life Technologies). cDNA was generated using the MuLV reverse transcriptase with random hexamers (both from Applied Biosystems, Carlsbad, California, USA), and gene-specific PCR was carried out with AmpliTaq DNA polymerase (Applied Biosystems) and primer pairs for Tbet, IFN-g, CXCR3, CXCL10, Foxp3, and b-actin as described previously [16] . The cycling conditions were as follows: initial denaturation at 941C for 2 min, denaturation at 941C for 30 s, annealing at 601C for 30 s, and elongation at 721C for 1 min a total of 35-40 cycles, followed by a final elongation at 721C for 5 min. RT-PCR products were resolved on 2% ethidium bromide-stained agarose gels (Sigma-Aldrich), and gel images were captured and analyzed using a GDS 8000 bioimaging system and Labworks software (UVP, LLC, Upland, California, USA). Band intensities for genespecific products were then normalized to b-actin, which served as the endogenous housekeeping gene between samples. Normalized transcript levels are reported as mean fold change (±SD) compared with the baseline values for each specific group at day 7 after tumor challenge.
Immunofluorescence microscopy
Six-micron tissue sections were prepared from tumors 20 days after MO5 inoculation, as described previously [16] . Briefly, sections were first blocked in 2% BSA and washed with 0.5% BSA/PBS in subsequent steps. The tumorderived vasculature was analyzed using rat-anti-mouse CD31 (BD Biosciences) and goat-anti-mouse VCAM-1 (R&D Systems, Minneapolis, Minnesota, USA) antibodies and a mixture of Alexa 488-conjugated donkey-anti-rat and CY3-conjugated donkey-anti-goat secondary antibodies (Life Technologies). After the removal of unbound probes by washing, sections were treated with DAPI (Sigma-Aldrich) to stain nuclei and imaged using an Olympus BX 51 Fluorescent Microscope (Olympus America, Melville, New York, USA). Immunofluorescence analysis was performed using Metamorph software (Molecular Devices, Sunnyvale, California, USA).
Statistical analysis
One-way analysis of variance was utilized to test for overall differences between groups (StatMate III; ATMS Co., Tokyo, Japan). Differences with a P-value less than 0.05 were considered significant.
Results
Axitinib enhances vaccine-initiated therapeutic protection against melanoma growth
To assess the effects of axitinib in vivo, C57BL/6 mice were inoculated subcutaneously in the right flank with the MO5 melanoma cell line (B16.OVA). Tumors were allowed to establish and grow progressively for 7 days, at which time, treatment was initiated. Groups of animals were left untreated or they received therapies consisting of axitinib and/or specific vaccination. Axitinib (0.5 mg/ daily) was administered through an oral gavage for 1 week, whereas vaccines (i.e. OVA peptide-pulsed DC.IL12 that we have previously shown to promote superior anti-OVA Tc1 responses in C57BL/6 mice [15, 16] ) were provided subcutaneously in the left flank (i.e. contralateral to the tumor) on days 7 and 14. Tumor growth was then monitored over time. Untreated animals developed rapidly progressive disease that required euthanasia by 20 days after tumor inoculation ( Fig. 1) . In contrast, MO5-bearing mice that were treated with single-agent vaccination or axitinib exhibited slowed tumor growth ( Fig. 1a) and an extended survival period of 10-15 days (Fig. 1b) . Interestingly, combination vaccine + axitinib therapy resulted in the greatest inhibition of tumor growth, which was superior to either component monotherapy ( Fig. 1a and b ; P < 0.05), with 40% of treated animals still alive 80 days after tumor inoculation ( Fig. 1b) .
Vaccine-induced effector T-cell infiltration and activity are improved by axitinib cotherapy
To provide a mechanistic explanation for the superiority of combined therapy, CD8 + T-cell frequency in treated tumor lesions was assessed over time. T cells were purified from enzymatically digested tumor material by CD3-MACS, and then stained and analyzed by flow cytometry for absolute CD8 + T-cell numbers (Fig. 2a ). As shown in Fig. 2b , the levels of bulk CD8 + T cells increased in all treated groups versus untreated mice by day 14 after the initiation of treatment, with the cotherapy yielding a superior level of such TIL (vs. either single modality after day 14 of the regimen; P < 0.05). Interestingly, when compared with untreated and vaccine alone cohorts, axitinib-containing cohorts displayed a prolonged period of increased CD8 + TIL infiltration/ presence. Using a specific H-2K b /OVA peptide tetramer probe, OVA-reactive CD8 + TIL frequencies were also assessed ( Fig. 2a and b ). Mice treated with either monotherapy were characterized by low, but detectable levels of tetramer + T cells within a week of initiating treatment. A marked increase in tetramer + CD8 + TIL was observed in the vaccination + axitinib cohort of treated animals, with B10% of all TIL showing specificity for the model tumor antigen OVA (P < 0.05 vs. all other cohorts). In concert with these therapyassociated changes in tetramer + T cells in tumor, we also determined that type-1 functionality (on the basis of IFN-g secretion) of such T cells isolated from either TIL or TDLN was enhanced and prolonged in animals treated with vaccines and axitinib, particularly those mice managed with the combination therapy ( Fig. 2c ).
Combination vaccine + axitinib therapy effectively reduces immunoregulatory cell populations in the treated melanoma microenvironment
As protective type-1 T cells would be anticipated to mediate more robust antitumor function under conditions that are not negatively influenced by regulatory cell populations [16] , we next examined the impact of single and combined modality treatment on myeloid-derived suppressor cells (MDSC) and Treg cells in melanomabearing mice. As shown in Fig. 3 , progressive growing, untreated tumors gradually accrued cells bearing MDSC (Gr1 + CD11b + ) and Treg (CD4 + Foxp3 + ) phenotypes in the TME over time. Each of the single modality therapies was able to reduce the rate at which regulatory cells accumulated within B16 lesions, and the use of combined vaccination + axitinib therapy led to sustained reductions in both MDSC and Treg populations within tumors in vivo.
Combination vaccine + axitinib therapy enforces a melanoma microenvironment conducive to type-1 T-cell recruitment/function in vivo
We have previously reported that protective type-1 antitumor CD8 + T cells express a CXCR3 + VLA-4 + phenotype that allows for recruitment into the TME on the basis of locoregional production of CXCR3 ligand chemokines (including CXCL9/Mig, CXCL10/IP10, and CXCL11/ITAC) and expression of the VLA-4 'ligand' VCAM-1 on tumor-associated vascular endothelial cells [16, 19] . To determine how single/combined therapies altered the expression of these mechanism-associated markers, we carried out RT-PCR and fluorescence microscopy analyses of B16 lesions harvested 20 days after the initiation of treatment protocols. We observed that all treatments, but particularly the combined vaccination + axitinib therapy, led to an increased preponderance of type-1 transcripts (i.e. Tbet, CXCR3, and IFN-g) and the type-1-recruiting chemokine CXCL10 (we also observed similar tendencies for CXCL9 and CXCL11 transcript expression; data not shown) in the melanoma microenvironment ( Fig. 4a ). As Tbet is considered a master regulator for type-1 function in T cells [20] , these data suggest that the cotreatment most favorably reconditions the TME to allow for the effective delivery of, and therapeutic activity mediated by, type-1 T cells. Such Tc1 activity may be further enhanced on the basis of the coordinately reduced presence of Treg, which is suggested by a prolonged elevation in the Tbet/Foxp3 transcript ratio in tumors treated with the vaccination + axitinib regimen (Fig. 4b) . Consistent with improved levels of type-1 TIL, we observed that CD31 + vascular endothelial cells in treated melanomas appeared activated (particularly in the vaccination + axitinib combination cohort) on the basis of their enhanced expression of VCAM-1 [21, 22] , as determined in immunofluorescence microscopy analyses (Fig. 4c ).
Discussion
The VEGF/VEGFR-signaling pathway is integral to endothelial migration and proliferation in melanomaassociated angiogenesis [2] . Preclinical studies support a Gr-1 MDSC
Treg
Combination vaccine + axitinib (VAC + AX) therapy reduces and/or prevents the accumulation of myeloid-derived suppressor cells (MDSC) and Treg suppressor cells in the melanoma microenvironment to a greater extent than the component single modality therapies. Isolated melanomas harvested and processed as described in Fig. 2 were analyzed by flow cytometry for the presence of regulatory cells expressing either a Treg (CD4 + Foxp3 + ) or an MDSC (CD11b + Gr1 + ) phenotype as described in the materials and methods section. variety of intervention strategies that may successfully disrupt VEGF/VEGFR signaling within the setting of melanoma [23] [24] [25] . This appears particularly salient as high levels of systemic VEGF correlate with a poor overall prognosis in melanoma patients [26, 27] , and the antagonist anti-VEGF antibody bevacizumab has shown a degree of antimelanoma efficacy when applied clinically [3] [4] [5] [6] .
An alternate method to mitigate the protumor impact of VEGF involves the application of small-molecule inhibitors (such as axitinib) that disrupt VEGFR-mediated signals after interaction with VEGF. Axitinib has been reported to primarily bind with a high affinity to the kinase domain of VEGFR-1, VEGFR-2, and VEGFR-3 expressed by selected human melanoma cells, where it inhibits ligand-dependent signaling [10] . In a multicenter phase II clinical trial including 32 patients with advanced-stage melanoma, axitinib monotherapy was associated with an 18.8% ORR (with one complete response and five partial responses), which persisted for a median duration of 5.9 months [11] . Although the ORRs in patients were similar to those obtained using more conventional treatment options such as chemotherapy and IL-2, axitinib appeared to exhibit efficacy for a larger number of patients on the basis of secondary endpoints. A significant proportion of axitinib-treated individuals Combined vaccine + axitinib (VAC + AX) therapy is more effective than single modality treatment in promoting a 'type-1' melanoma microenvironment. (a) Total RNA was purified from single-cell suspensions of MO5 tumors harvested on the indicated days as described in Fig. 2 . RT-PCR was then performed using primer pairs specific to the type-1 associated markers Tbet, IFN-g, CXCR3, and CXCL10. PCR products were resolved through electrophoresis, imaged, and band intensities were normalized to the intensity of b-actin-specific amplification from paired samples. Data are presented as the fold change in transcript levels (mean±SD) compared with the baseline values from the same cohort on the day of treatment initiation (i.e. day 7 after tumor challenge). *P < 0.05 versus all groups. (b) RT-PCR analysis was performed using Tbet-specific and Foxp3-specific primer pairs as outlined in (a) and the materials and methods section, with the mean ratio of Tbet/Foxp3 transcript levels reported (±SD) on the indicated days after treatment initiation. (c) Day 20 melanomas were harvested from all groups and tissue sections analyzed by immunofluorescence microscopy for the expression of CD31 and VCAM-1 as outlined in the materials and methods section. Cell nuclei were imaged by staining with DAPI. Mean±SD absolute numbers of CD31 + VCAM-1 + cells per high-power field (HPF) over 10 HPFs/slide are reported. *P < 0.05 versus all other groups. INF g, interferon g.
Axitinib/vaccine cotherapy of melanoma Bose et al. 241 showed reductions in the plasma concentrations of soluble VEGFR-2 and VEGFR-3 after two cycles of axitinib-based therapy [11] . At least 40% of patients also developed hypertension during exposure to axitinib, which has emerged as a biomarker for therapeutic antiangiogenic effectiveness [28] [29] [30] .
At present, it remains unclear why axitinib therapy does not mediate a higher rate of durable ORRs in advancedstage melanoma patients. Although VEGF/VEGFR-binding events represent an important pathway involved in tumor vasculature formation [31] , a potential explanation underlying the clinical limitations of axitinib might be taken from the general failure of single-agent bevacizumab as a cancer treatment [1, 32, 33] . In cancer patients, bevacizumab impacts predominantly immature blood vessels and, upon vascular 'normalization' and stabilization of a mature vascular system supported by compensatory non-VEGFR-signaling pathways in the melanoma microenvironment, patient relapse can occur [33] [34] [35] [36] . In the case of bevacizumab, this has led to extensive research for effective second-line or cotherapeutic agents that mediate antitumor effects by nonoverlapping mechanisms. Notably, the normalization of the tumor vasculature by many antiangiogenic drugs leads to a transient state that is permissive for the improved delivery of chemotherapeutic agents and immune cells into the TME, which may enhance the likelihood for ORRs [3] [4] [5] [6] 33, 37, 38] . It will, therefore, be interesting to assess whether future clinical trials incorporating combinational axitinib strategies support this 'vascular normalization' hypothesis and lead to improved clinical responsiveness over treatment with single-agent axitinib. Currently, a phase II trial is recruiting metastatic melanoma patients for axitinib/chemotherapy combined therapy (Clinicaltrials.gov identifier: NCT01174238).
Active vaccination should also be considered for inclusion in combination treatment with anti-VEGF-targeted strategies, as immunization may elicit protective Tc1 responses that may be consequently recruited into the TME on the basis of the locoregional influence of drugs such as bevacizumab and axitinib, among others. The current study reports the novel result that axitinib and specific vaccination against a (model) tumor-associated antigen activates and coordinates therapeutic immunity against established melanomas. Although the individual peptide-based vaccine and axitinib monotherapies slowed tumor growth to some degree, coadministration of vaccine + axitinib led to a marked increase in type-1 immune cell infiltration into B16 melanomas in association with the extended overall survival or treated animals. Improved levels of vaccine-induced CD8 + TIL observed in animals treated with the combination therapy were associated with the local activation of tumor vascular endothelial cells (on the basis of VCAM-1 expression that serves as a ligand for type-1 T cells expressing the VLA-4 integrin [21, 22] ) and the production of CXCR3 ligand chemokines (such as CXCL10/IP10 that recruits CXCR3 + type-1 T cells [16] ). In addition, vaccine/ axitinib therapy caused marked decreases in the levels of cells bearing immunosuppressive Treg and MDSC phenotypes in the TME, which were sustained at low levels for the duration of the study. The removal of MDSC and Treg allows for effector type-1 TIL to mediate antitumor activity in a largely unopposed manner [39, 40] , as suggested by our observation for a markedly increased Tbet/Foxp3 transcript ratio in the TME after treatment with the combined regimen.
Overall, axitinib appears to represent a potent 'adjuvant' for use in melanoma therapy, in the sense that it reconditions the TME toward a state that is receptive to the therapeutic action of protective type-1 immunity. Our results support the use of combined vaccine + axitinib protocols in prospective clinical trials for the treatment of patients with advanced-stage melanoma.
